| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Exagen Inc. Common Stock$4.25
-0.15 (-3.4%)
Market Cap
72.88 M
EPS
-0.92
P/E Ratio
-3.29 $
Value Trade
1.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
17.31 M
R&D Expenses
1.55 M
Operating CF
-10.42 M
Total Assets
51.96 M
Total Liabilities
37.52 M
Equity
14.43 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
21.51 M
Monthly Burn
3.47 M
Runway
3.6 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
129.75 K
52 Week Range
2.59 - 12.23
% held by Insiders
38.91 %
% held by Institutions
43.61 %
Enterprise Value
68.33 M
Total Shares
22.68 M
Short %
6.66 %
Float Shares
14.69 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-XGN
Jul 28, 2026▼ -3.4%today
Exagen Inc. to Participate in Upcoming Investor Conference
Exagen Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The management will engage in a Fireside Chat at 8:30 am ET, which will be available via webcast. Exagen focuses on autoimmune diagnostics and aims to improve patient care through its advanced testing solutions.
Read more →-XGN
Jul 21, 2026Exagen to Announce Second Quarter Financial Results on August 4, 2026
Exagen Inc. will announce its financial results for Q2 2026 on August 4, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 a.m. ET. The call will be hosted by CEO John Aballi and CFO Jeff Black, providing insights into the company's performance.
Read more →-XGN
Jun 1, 2026▲ +7.4%on this news
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Exagen Inc. announced the publication of a systematic review confirming that its AVISE Lupus algorithm significantly outperforms conventional serologic tests in diagnosing Systemic Lupus Erythematosus (SLE). The study, involving over 1,200 patients, demonstrated enhanced sensitivity and specificity, identifying 25% of patients missed by traditional methods. This reinforces Exagen's competitive position in autoimmune diagnostics.
Read more →-XGN
May 11, 2026▲ +34.9%on this news
Exagen Inc. Reports First Quarter 2026 Results
Exagen Inc. reported strong financial results for Q1 2026, with record revenues of $17.3 million, a 12% increase from the previous year. The company also saw a 10% rise in AVISE CTD test volume and improved its adjusted EBITDA loss. Exagen maintains a positive outlook for the full year, expecting revenues between $70 million and $73 million.
Read more →-XGN
Apr 27, 2026Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Exagen Inc. will announce its financial results for Q1 2026 on May 11, 2026, before market opening. CEO John Aballi and CFO Jeff Black will host a conference call at 8:30 a.m. ET to discuss the results. The company specializes in autoimmune diagnostics and aims to enhance patient care through innovative testing solutions.
Read more →-XGN
Mar 3, 2026Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. announced its participation in two upcoming investor conferences, including the KeyBank Capital Markets Healthcare Forum and the Roth Capital Conference. The events will provide opportunities for investor meetings and discussions about the company's innovative autoimmune testing solutions. Exagen aims to enhance awareness of its diagnostic capabilities for autoimmune conditions.
Read more →-XGN
Feb 24, 2026Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen Inc. will announce its financial results for Q4 and the full year of 2025 on March 10, 2026. The announcement will be made before the market opens, followed by a conference call at 8:30 a.m. ET. The company specializes in autoimmune diagnostics and aims to improve patient care through innovative testing solutions.
Read more →-XGN
May 9, 2025▼ -7.3%on this news
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter s Option to Purchase Additional Shares
Exagen Inc. has successfully closed a public offering, raising approximately $20.2 million by selling 502,500 additional shares at $5.25 each. This offering follows an earlier announcement of a sale of 3,350,000 shares, contributing to the company's financial growth. Canaccord Genuity served as the sole bookrunner for this transaction. The public offering was conducted under a shelf registration statement previously approved by the Securities and Exchange Commission.
Read more →-XGN
May 7, 2025▲ +6.4%on this newsshared move
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. announced a proposed underwritten public offering of its common stock aimed at strengthening its financial position. The offering includes an option for the underwriter to purchase an additional 15% of shares. It will be made under a previously filed shelf registration statement with the SEC. However, the company warns that the offering is subject to market conditions and lacks assurances regarding its completion or actual terms.
Read more →-XGN
Apr 28, 2025▲ +7.1%on this news
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors $25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Ca
Exagen Inc. has finalized a senior secured credit facility agreement with Perceptive Advisors, securing an initial $25 million to refinance existing debt and enhance its financial stability. The total credit facility amounts to $75 million, with additional funding options available. This strategic partnership is aimed at supporting Exagen's growth initiatives in the autoimmune diagnostics market. However, the company's future performance is contingent on achieving certain milestones and overcoming industry challenges.
Read more →-XGN
Aug 20, 2024▼ -5.9%on this news
real-world evidence confirms that AVISE testing enables decisive clinical action superior to the current standard of care
The article discusses the confirmation of real-world evidence regarding AVISE testing. It highlights that this testing enables clinical actions that are superior to the current standard of care. However, the article lacks specific details or data to support these claims.
Read more →-XGN
Oct 25, 2021Exagen Inc. Announces $27.2 Million Debt Refinancing
Exagen Inc. Announces $27.2 Million Debt Refinancing SAN DIEGO, CA - Exagen Inc. (Nasdaq XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innova
Read more →Competitive Position
How XGN ranks across every disease it competes inCompetitive Position is a premium feature
See how XGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial